Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-18

I like this bit from the announcement - I agree that it eases the pressure somewhat 0n the funding going forward!

"These revised clinical plans have substantially reduced the Company's budgeted trial costs, and with the expected additional R&D tax incentive rebates, the Company now estimates that it can fund both the Company and the trial into 4Q’23. The Company will move forward with the study initiation as outlined above. There is an approximately mid-single digit A$m additional future cash required to get to the time point of the reporting of trial results and the Company will update the market upon confirmation of the amount of such additional future funding and how it will be sourced."

A game-changer for the trial initiation!

GLTAH
.